Home » EMA to Revise Multiplicity Points-to-Consider Guideline
EMA to Revise Multiplicity Points-to-Consider Guideline
June 7, 2012
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use is seeking public input as it works to update its points-to-consider document on multiplicity issues in clinical trials.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor